1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.

Pfizer says U.S. court invalidates Celebrex patent; generics loom

  1. ZenobiaSky
    (Reuters) - A U.S. court ruled invalid a patent covering Pfizer Inc's blockbuster Celebrex painkiller, the drugmaker said, giving generic rivals an earlier U.S. entry that analysts estimated could cost the company $3 billion in revenue by the end of 2015.

    Pfizer shares closed down 1.4 percent on the New York Stock Exchange.

    Pfizer said it would appeal the ruling, made by the U.S. District Court for the Eastern District of Virginia, which invalidated a patent covering how Celebrex is administered to treat osteoarthritis.

    Celebrex has annual global sales of about $3 billion, including $2 billion in the United States. It is the fourth-biggest product for Pfizer, which has total annual company sales of about $52 billion.

    Pfizer, in its full-year 2014 profit forecast, had assumed Celebrex would maintain its U.S. marketing exclusivity through December 2, 2015 based on the so-called method of use patent, Morningstar analyst Damien Conover said.

    He said the court's decision, if not overturned on appeal, could cost Pfizer $1 billion in revenues this year and $2 billion next year.

    Conover said he had been surprised by Pfizer's confidence in the method of use patent, because they are rarely upheld by U.S. courts. The drug's basic chemical patent lapses on May 30, 2014, and generic companies including Teva Pharmaceuticals Inc and Mylan Pharmaceuticals Inc have sought approval to sell their cheaper versions at that point.

    "It seems likely that odds are in favor of generics launching early," Sanford Bernstein analyst Tim Anderson said in a research note.

    Reporting By Vrinda Manocha in Bangalore and Ransdell Pierson in New York
    Wed Mar 12, 2014 4:35pm EDT

    The Newhawks Crew


    I suggest that people using either, who have not yet done so, should Google: "Celebrex; hazards" & "Dr. Mercola 13 Raises Red Flags on the 13 Most Dangerous Drugs", where it is listed at no. 5.

    It states:
    5. Celebrex (Pfizer)
    Used by arthritis sufferers as a painkiller, Celebrex has been associated with increased risks of kidney problems, liver damage, and stomach bleeding. According to a 2005 study, those taking 200 mg of Celebrex twice a day more than doubled their risk of dying of cardiovascular disease, while those taking 400 mg twice a day more than tripled their risk.
To make a comment simply sign up and become a member!